ArticleBiosensors & bioelectronics2020
Rapid and quantitative detection of SARS-CoV-2 specific IgG for convalescent serum evaluation.
Article in Biosensors & bioelectronics, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 42 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
42 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Antibody tests for identification of current and past infection with SARS-CoV-2.The Cochrane database of systematic reviews · 2022Pooled it
- Development of a Miniaturized, Automated, and Cost-Effective Device for Enzyme-Linked Immunosorbent Assay.Sensors (Basel, Switzerland) · 2025Article
- Universal Nanopore Sensor for Amplification-Free and Label-Free Detection of Molecular Biomarkers.ACS sensors · 2025Article
- Fast and Sensitive Detection of Anti-SARS-CoV-2 IgG Using SiOBiomolecules · 2024Article
- Advancing Microfluidic Immunity Testing Systems: New Trends for Microbial Pathogen Detection.Molecules (Basel, Switzerland) · 2024Review
- Three-Dimensional Microfluidic Capillary Device for Rapid and Multiplexed Immunoassays in Whole Blood.ACS sensors · 2024Article
- Molecular characterization of SARS-CoV-2 nucleocapsid protein.Frontiers in cellular and infection microbiology · 2024Review
- Flower-like WSeAnalytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2023Article
- Development of nucleocapsid-specific monoclonal antibodies for SARS-CoV-2 and their ELISA diagnostics on an automatic microfluidic device.Sensors and actuators. B, Chemical · 2023Article
- Microfluidic-based technologies for diagnosis, prevention, and treatment of COVID-19: recent advances and future directions.Biomedical microdevices · 2023Review
- Application of microfluidic technologies on COVID-19 diagnosis and drug discovery.Acta pharmaceutica Sinica. B · 2023Review
- The SARS-CoV-2 nucleocapsid protein: its role in the viral life cycle, structure and functions, and use as a potential target in the development of vaccines and diagnostics.Virology journal · 2023Review
- The SARS-CoV-2 specific IgG antibodies biophotonic sensor.Journal of biophotonics · 2023Article
- Merging microfluidics with luminescence immunoassays for urgent point-of-care diagnostics of COVID-19.Trends in analytical chemistry : TRAC · 2022Review
- Sample-to-Answer Immuno-Magnetic Assay Using Thermally Responsive Alkane Partitions.Biosensors · 2022Article
- An impedimetric biosensor for COVID-19 serology test and modification of sensor performance via dielectrophoresis force.Biosensors & bioelectronics · 2022Article
- A comprehensive review of COVID-19 detection techniques: From laboratory systems to wearable devices.Computers in biology and medicine · 2022Review
- Anti-SARS-CoV-2 IgM/IgG antibodies detection using a patch sensor containing porous microneedles and a paper-based immunoassay.Scientific reports · 2022Article
- Regenerable and high-throughput surface plasmon resonance assay for rapid screening of anti-SARS-CoV-2 antibody in serum samples.Analytica chimica acta · 2022Article
- Rapid biosensing SARS-CoV-2 antibodies in vaccinated healthy donors.Biosensors & bioelectronics · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Convalescent serum with a high abundance of neutralization IgG is a promising therapeutic agent for rescuing COVID-19 patients in the critical stage. Knowing the concentration of SARS-CoV-2 S1-specific IgG is crucial in selecting appropriate convalescent serum donors. Here, we present a portable microfluidic ELISA technology for rapid (15 min), quantitative, and sensitive detection of anti-SARS-CoV-2 S1 IgG in human serum with only 8 μL sample volume. We first identified a humanized monoclonal IgG that has a high binding affinity and a relatively high specificity towards SARS-CoV-2 S1 protein, which can subsequently serve as the calibration standard of anti-SARS-CoV-2 S1 IgG in serological analyses. We then measured the abundance of anti-SARS-CoV-2 S1 IgG in 16 convalescent COVID-19 patients. Due to the availability of the calibration standard and the large dynamic range of our assay, we were able to identify "qualified donors" for convalescent serum therapy with only one fixed dilution factor (200 ×). Finally, we demonstrated that our technology can sensitively detect SARS-CoV-2 antigens (S1 and N proteins) with pg/mL level sensitivities in 40 min. Overall, our technology can greatly facilitate rapid, sensitive, and quantitative analysis of COVID-19 related markers for therapeutic, diagnostic, epidemiologic, and prognostic purposes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.